Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?

QST, in particular CDT, HP 5 and HP 0.5 modalities, seems a good tool to identify subclinical neuropathy in ATTRv amyloidosis carriers, with CDT showing a higher sensitivity to detect and early neuropathic involvement.